Christopher Richard Anzalone - 01 Jan 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
01 Jan 2022
Net transactions value
$0
Form type
4
Filing time
04 Jan 2022, 20:22:50 UTC
Previous filing
23 Dec 2021
Next filing
07 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Award $0 +800,000 +25% $0.000000 4,045,828 01 Jan 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined goals related to the advancement of the Company's market capitalization that must be achieved within four years. If the goals are not met within the required time periods, the award will be forfeited in part or in whole.
F2 Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.